Embolic Protection Devices during percutaneous cardiac procedures (PCI and TAVI)

Series
Cardiovascular
Status
Published
Date
Number of report
060

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of Embolic Protection Devices during percutaneous cardiac procedures. 

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

The following clinical situations are considered: 

  • Use of Embolic Protection Device during percutaneous transluminal coronary angioplasty with insertion of single bare metal stent
  • Use of Embolic Protection Device during percutaneous transluminal transcatheter aortic valve replacement

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of Embolic Protection Devices for percutaneous cardiac procedures (PCI and TAVI):

  • Allium Medical (WIRION EPD)
  • Boston Scientific (FilterWire EZ)
  • Claret Medical (Sentinel)
  • Contego Medical
  • Cordis (ANGIOGUARD)
  • Innovative Cardiovascular Solutions (Emblock)
  • Keystone Heart Ltd (TriGuard)
  • Transverse Medical (POINT-GUARD)

Table of content is not available at the moment. Report is still ongoing.

25

Apr 2022

On March 31, 2022, NHS Digital released HRG4+ Local Payment Grouper for 2022/23 for use from April 01, 2022. In general, there are significant changes in base HRG design. A total of 120 new HRGs were created, and multiple HRGs were removed, so the total number increased by 62 from 2,838 to 2,900.

Read more

15

Feb 2022

In January 2022, the Basque Office for Health Technology Assessment (OSTEBA) released an HTA report aiming to assess and compare the efficacy, effectiveness, and safety of the mechanical circulatory support devices most used in the healthcare setting for the treatment and prevention of cardiogenic shock, including Impella® devices, intra-aortic balloon pumps, and extracorporeal membrane oxygenation.

Read more

31

Jan 2022

On January 20, 2022, the Academy of Medical Royal Colleges (AoMRC) launched a consultation on the latest set of guidance (List 3) of the Evidence-based Interventions (EBI) Programme. EBI program develops guidance sets (Lists) for tests, treatments, and procedures based on recommendations from the Expert Advisory Committee and NICE assessments. Proposed List 3 covers 17 interventions across a range of medical specialties, including cardiology, ophthalmology, urology, and others. The deadline for comments submission is March 31, 2022.

Read more

17

Dec 2021

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) systematically evaluates healthcare technologies and practices from medical, economic, ethical, and social standpoints. The following assessments were initiated in the third quarter of 2021: ultrasound-guided arterial catheters insertion in adults, the basis for national guidelines for heart disease. The final reports will be published on the SBU website upon completion

Read more

15

Dec 2021

In 2015, the Federal Office for Public Health launched an HTA program intending to reassess the benefits already reimbursed by compulsory health insurance. The following ongoing re-evaluations are in progress: multigene expression tests in breast cancer, cardiac catheterization for coronary artery disease, invasive procedures for coronary artery disease, removal of osteosynthesis materials, etc.

Read more
(we accept only company emails)